Allopurinol

also known as ALLO · 1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one · Acepurin · Allopurinol (Allosig, Progout, Zyloprim) · Allopurinol component of duzallo · ALLOPURINOL SODIUM · Allopurinol sodium salt · Allopurinol Tablet · +25 more

Small molecule targets XDH via inhibition

Developed for: gout · chronic kidney disease · hypertensive disorder · manic bipolar affective disorder · cardiovascular disorder · nephrolithiasis · congestive heart failure · impaired renal function disease
+54 more
· obstructive sleep apnea syndrome · schizophrenia · type 2 diabetes mellitus · acute coronary syndrome · acute kidney injury · acute lymphoblastic leukemia · adenine phosphoribosyltransferase deficiency · adenylosuccinate lyase deficiency · adult acute lymphoblastic leukemia · brain hypoxia - ischemia · childhood acute lymphoblastic leukemia · coronary artery disorder · cutaneous leishmaniasis · diabetes mellitus, noninsulin-dependent, 2 · diabetic autonomic neuropathy · diabetic kidney disease · diastolic heart failure · dilated cardiomyopathy · essential hypertension · fetal growth restriction · hand-foot syndrome · heart failure · IgA glomerulonephritis · inflammatory bowel disease · intermediate coronary syndrome · ischemic stroke · leishmaniasis · leukemia · lymphoma · metabolic dysfunction-associated steatotic liver disease · metabolic syndrome X · resistant hypertension · schizoaffective disorder · small cell lung carcinoma · symptomatic heart failure · tumor lysis syndrome · ulcerative colitis · cirrhosis of liver · congenital heart disease · diabetes mellitus · disease related to solid organ transplantation · end stage renal failure · hepatic encephalopathy · infectious peritonitis · ischemic disease · kidney disorder · major depressive disorder · muscular atrophy · nephrolithiasis, calcium oxalate · peripheral arterial disease · prediabetes syndrome · renal osteodystrophy · type 1 diabetes mellitus · varicose disease
Investigated by: AstraZeneca · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Ardea Biosciences, Inc. · National Heart, Lung, and Blood Institute (NHLBI) · Arthrosi Therapeutics · Baylor University
+93 more
· Parexel · The University of Texas at Arlington · Cedars-Sinai Medical Center · Juvenile Diabetes Research Foundation · Sanofi · Sheba Medical Center · Sun Yat-sen University · UMC Utrecht · University of Michigan · University of Missouri-Columbia · Washington University School of Medicine · Aalborg University Hospital · Aarhus University Hospital · Ain Shams University · Albert Einstein College of Medicine · Alessandro Doria · Assistance Publique - Hôpitaux de Paris · Atom Therapeutics Co., Ltd · BCDiabetes.Ca · Beni-Suef University · BioCryst Pharmaceuticals · Brigham and Women's Hospital · British Heart Foundation · Bronx Psychiatric Center · Cairo University · Combined Military Hospital, Pakistan · Emory University · Goethe University · Guangzhou General Hospital of Guangzhou Military Command · Harvard School of Public Health (HSPH) · Hillel Yaffe Medical Center · Hospices Civils de Lyon · Hospital Espirita de Porto Alegre · Hvidovre University Hospital · Instituto Nacional de Cardiologia Ignacio Chavez · Instituto Nacional de Rehabilitacion · InventisBio Co., Ltd · Istanbul University · Johns Hopkins University · Joslin Diabetes Center · La Fe Health Research Institute · Landspitali University Hospital · M.D. Anderson Cancer Center · Maisonneuve-Rosemont Hospital · Mansoura University · Mayo Clinic · NHS Greater Glasgow and Clyde · National Alliance for Research on Schizophrenia and Depression · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National University Hospital, Singapore · Northwestern University · Odense University Hospital · Open Medicine Institute · Sanglah General Hospital · Sant Pau Research Institute · Shifa Ul Mulk Memorial Hospital · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Stanley Medical Research Institute · Steno Diabetes Center Copenhagen · Stephen McSwiggan · Sydvestjysk Hospital Esbjerg · URC-CIC Paris Descartes Necker Cochin · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · University of Alabama at Birmingham · University of Alberta · University of Athens · University of Calgary · University of California, San Francisco · University of Colorado, Denver · University of Copenhagen · University of Dundee · University of Glasgow · University of Minnesota · all 99 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Duzallo	—	2018-08-23	europa.eu ↗
Approved	US (FDA)	ZYLOPRIM	—	1966-08-19	fda.gov ↗

Trials 79 · started per year

today

US approved 1966

EU approved 2018

1965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT05360628	Nov 2021 → Feb 2022	—	InventisBio Co., Ltd	Completed	No outcome recorded
Phase 0	NCT04026776	Sep 2020 → Dec 2026 expected	hypertensive disorder	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 0	NCT03076684	Mar 2017 → Dec 2018	—	University of Missouri-Columbia	Withdrawn	No outcome recorded Stop: Business
Phase 0	NCT02046694	Jan 2014 → Apr 2020	acute lymphoblastic leukemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 113 trials · 1 missed
Phase 1	NCT07367971	Jan → Jul 2026 overdue	gout	Atom Therapeutics Co., Ltd	Recruiting	No outcome recorded
Phase 1	NCT05049863	Feb 2023 → Nov 2024	small cell lung carcinoma	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1	NCT04550234	Apr → Jul 2021	chronic kidney disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT04532918	Sep → Nov 2020	chronic kidney disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT04347005	Jan → Jul 2019	—	Arthrosi Therapeutics	Completed	No outcome recorded
Phase 1	NCT03836599	Jan → Apr 2019	chronic kidney disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03680404	Oct 2018 → Feb 2020	vascular disorder	The University of Texas at Arlington	Completed	No outcome recorded
Phase 1	NCT03680573	Jan → May 2018	cardiovascular disorder	The University of Texas at Arlington	Completed	No outcome recorded
Phase 1	NCT03680638	Sep 2016 → Oct 2017	cardiovascular disorder, isoproterenol-mediated vasodilatation	The University of Texas at Arlington	Completed	No outcome recorded
Phase 1	NCT02700347	Feb → Apr 2016	tuberculosis	National University Hospital, Singapore	Completed	Missed primary
Phase 1	NCT02581553	Oct 2015 → Jul 2016	—	Ardea Biosciences, Inc.	Completed	No outcome recorded
Phase 1	NCT02279641	Nov 2014 → Apr 2015	gout	Ardea Biosciences, Inc.	Completed	No outcome recorded
Phase 1	NCT00849368	Jan 2009 → Sep 2011	inflammatory bowel disease	University of Zurich	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT06056570	Oct 2023 → Jun 2024	gout	Urica Therapeutics Inc.	Completed	Mixed
Phase 1/2	NCT03506919	Jan → Apr 2018	—	Shifa Ul Mulk Memorial Hospital	Unknown	No outcome recorded
Phase 1/2	NCT00288171	Feb 2006 → Jan 2008	hypertensive disorder	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Withdrawn	No outcome recorded
Phase 1/2	NCT00281255	Jun 2003 → Jun 2013	congestive heart failure, dilated cardiomyopathy	University of Pennsylvania	Withdrawn	No outcome recorded
Phase 217 trials · 4 met primary · 2 missed
Phase 2	NCT05888233	Sep 2024 → Apr 2026	resistant hypertension, symptomatic heart failure	VA Office of Research and Development	Completed	No outcome recorded
Phase 2	NCT05253833	Aug 2022 → Aug 2024	gout	Arthrosi Therapeutics	Completed	No outcome recorded
Phase 2	NCT04327024	May 2020 → Apr 2022	diastolic heart failure	AstraZeneca	Completed	Missed primary
Phase 2	NCT04155918	Feb → Sep 2020	gout	Arthrosi Therapeutics	Completed	No outcome recorded
Phase 2	NCT03776656	Oct 2019 → Jun 2022	adenylosuccinate lyase deficiency	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT03990363	Jul 2019 → Nov 2021	chronic kidney disease	AstraZeneca	Completed	Missed primary
Phase 2	NCT03648996	Nov 2018 → Mar 2022	type 2 diabetes mellitus	University of Missouri-Columbia	Completed	No outcome recorded
Phase 2	NCT03022747	Jan 2017 → Dec 2018	childhood acute lymphoblastic leukemia	Vastra Gotaland Region	Unknown	No outcome recorded
Phase 2	NCT02498652	Jul → Nov 2015	gout	Ardea Biosciences, Inc.	Completed	No outcome recorded
Phase 2	NCT02078219	Jan 2014 → Mar 2015	gout	AstraZeneca	Completed	Met primary
Phase 2	NCT01609166	Jul 2011 → Sep 2012	hand-foot syndrome	Sant Pau Research Institute	Completed	No outcome recorded
Phase 2	NCT01200485	Apr 2011 → Jul 2016	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01129648	May → Nov 2010	gout	BioCryst Pharmaceuticals	Completed	Met primary
Phase 2	NCT00288158	Sep 2008 → Jan 2011	hypertensive disorder, obesity disorder	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00181155	Nov 2004 → Dec 2010	congestive heart failure	Johns Hopkins University	Completed	Met primary
Phase 2	NCT00288184	Sep 2004 → Mar 2007	essential hypertension	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	Met primary
Phase 2	NCT00004755	Sep 1995 → ?	leishmaniasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT02038179	Jul 2014 → Aug 2018	hypertensive disorder	University of Alabama at Birmingham	Completed	Mixed
Phase 311 trials · 2 met primary · 4 missed
Phase 3	NCT04012294	Aug 2019 → Jul 2020	musculoskeletal system disorder	Instituto Nacional de Cardiologia Ignacio Chavez	Unknown	No outcome recorded
Phase 3	NCT03101800	Dec 2016 → Nov 2019	ulcerative colitis	Hvidovre University Hospital	Unknown	Met primary
Phase 3	NCT02017171	Feb 2014 → Jul 2019	coronary artery disorder, diabetic kidney disease	Alessandro Doria	Completed	Missed primary
Phase 3	NCT01987570	Apr 2012 → Jul 2016	—	La Fe Health Research Institute	Completed	No outcome recorded
Phase 3	NCT02533648	Sep 2011 → Feb 2016	type 2 diabetes mellitus	Hospices Civils de Lyon	Completed	No outcome recorded
Phase 3	NCT01320722	Mar 2011 → May 2015	hypertensive disorder, impaired renal function disease, obesity disorder	Brigham and Women's Hospital	Completed	Missed primary
Phase 3	NCT01092221	May 2010 → Apr 2011	manic bipolar affective disorder	Sheba Medical Center	Completed	No outcome recorded
Phase 3	NCT00189007	Oct 2009 → Dec 2011	brain hypoxia - ischemia	UMC Utrecht	Unknown	Missed primary
Phase 3	NCT00230178	Apr 2004 → Dec 2007	cancer, tumor lysis syndrome	Sanofi	Completed	Met primary
Phase 3	NCT00199043	May 2003 → May 2008	adult acute lymphoblastic leukemia	Goethe University	Completed	No outcome recorded
Phase 3	NCT00116207	Jan 2000 → Sep 2009	diabetic autonomic neuropathy	University of Michigan	Completed	Missed primary

Phase 420 trials · 1 met primary · 3 missed
Phase 4	NCT05540184	Sep 2022 → Sep 2025	acute kidney injury	Beni-Suef University	Unknown	No outcome recorded
Phase 4	NCT05365477	Aug 2022 → Sep 2025	nephrolithiasis	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT05474560	Jan 2022 → Jan 2023	metabolic dysfunction-associated steatotic liver disease	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT05414669	Aug 2020 → Mar 2021	nephrolithiasis	Sanglah General Hospital	Completed	No outcome recorded
Phase 4	NCT03745729	Mar 2019 → Jul 2022	acute coronary syndrome	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Completed	No outcome recorded
Phase 4	NCT03195153	Mar → Jun 2017	diabetes mellitus, noninsulin-dependent, 2	University of Roma La Sapienza	Unknown	No outcome recorded
Phase 4	NCT02956278	Nov 2016 → Mar 2018	gout	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT02477488	Jun → Aug 2015	gout, impaired renal function disease	Maisonneuve-Rosemont Hospital	Completed	No outcome recorded
Phase 4	NCT02373384	Feb 2015 → Feb 2017	nephrolithiasis	Mansoura University	Completed	No outcome recorded
Phase 4	NCT02797028	Jan 2015 → Oct 2016	cardiovascular disorder	Guangzhou General Hospital of Guangzhou Military Command	Unknown	No outcome recorded
Phase 4	NCT02122718	May 2014 → Feb 2021	ischemic stroke	NHS Greater Glasgow and Clyde	Completed	Missed primary
Phase 4	NCT02752633	May 2013 → May 2015	adenine phosphoribosyltransferase deficiency	Landspitali University Hospital	Completed	No outcome recorded
Phase 4	NCT01457820	Apr 2012 → Mar 2015	intermediate coronary syndrome	Stephen McSwiggan	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01391325	Jul 2011 → Jan 2013	gout	Ardea Biosciences, Inc.	Completed	No outcome recorded
Phase 4	NCT00864825	Aug → Dec 2009	schizoaffective disorder, schizophrenia	Sheba Medical Center	Completed	Missed primary
Phase 4	NCT00732251	Aug 2008 → Jan 2012	manic bipolar affective disorder	Cedars-Sinai Medical Center	Terminated	No outcome recorded
Phase 4	NCT00512057	Jun 2008 → Jun 2010	metabolic syndrome X	University of Dundee	Completed	No outcome recorded
Phase 4	NCT00643123	Sep 2007 → Jun 2010	manic bipolar affective disorder	Cedars-Sinai Medical Center	Completed	Missed primary
Phase 4	NCT00560079	Nov 2003 → Apr 2005	manic bipolar affective disorder	Hospital Espirita de Porto Alegre	Completed	Met primary
Phase 4	NCT00477789	—	heart failure	University of Verona	Completed	No outcome recorded

Phase not applicable9 trials
—	NCT03601260	Aug → Dec 2018	gout	Hillel Yaffe Medical Center	Unknown	No outcome recorded
—	NCT01188005	Aug → Oct 2010	obstructive sleep apnea syndrome	University of Athens	Unknown	No outcome recorded
—	NCT00978653	Apr 2008 → Mar 2009	chronic kidney disease	Istanbul University	Completed	No outcome recorded
—	NCT00480883	Jan → Jun 2008	cutaneous leishmaniasis	Combined Military Hospital, Pakistan	Completed	No outcome recorded
—	NCT00793585	Jul 2007 → Jun 2009	IgA glomerulonephritis	Sun Yat-sen University	Completed	No outcome recorded
—	NCT00346463	Jul 2006 → Jul 2013	fetal growth restriction	UMC Utrecht	Unknown	No outcome recorded
—	NCT00823199	Nov 2005 → Aug 2008	schizophrenia	Bronx Psychiatric Center	Completed	No outcome recorded
—	NCT01775098	? → Dec 2012	gout	University of Sherbrooke	Withdrawn	No outcome recorded Stop: Business
—	NCT00214084	—	obstructive sleep apnea syndrome	University of Wisconsin, Madison	Withdrawn	No outcome recorded
Comparator or background therapy101 trials
Phase 1	NCT04256629 Background	Mar → Aug 2020	—	AstraZeneca	Completed	Met primary
Phase 1	NCT00513474 Background	Jan 2008 → Feb 2013	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1	Massachusetts General Hospital	Completed	Met primary
Phase 1	NCT00602693 Background	Jul 2007 → Sep 2014	leukemia, myelodysplastic syndrome, plasma cell myeloma	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT07033533 Comparator	Jun 2023 → Mar 2024	cirrhosis of liver	Tanta University	Completed	No outcome recorded
Phase 1/2	NCT02953509 Background	Nov 2016 → Mar 2024	non-Hodgkin lymphoma	Gilead Sciences	Terminated	No outcome recorded
Phase 1/2	NCT00061945 Background	Jun 2003 → Dec 2007	B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT05805605 Background	May 2023 → Oct 2027 expected	Burkitt lymphoma, T-cell non-Hodgkin lymphoma, acute biphenotypic leukemia, acute undifferentiated leukemia +8	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT05665699 Background	Apr 2023 → Jul 2025	gout	InventisBio Co., Ltd	Completed	No outcome recorded
Phase 2	NCT05536349 Background	Dec 2022 → Apr 2028 expected	leukemia	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT04621929 Background	Mar 2021 → Nov 2024	obesity disorder, prediabetes syndrome, type 2 diabetes mellitus, urolithiasis	University of Florida	Completed	No outcome recorded
Phase 2	NCT03865407 Comparator	Mar 2019 → Oct 2020	chronic kidney disease	Virginia Commonwealth University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03767322 Comparator	Dec 2018 → Oct 2019	acute kidney injury	Instituto Nacional de Cardiologia Ignacio Chavez	Unknown	No outcome recorded
Phase 2	NCT03570983 Background	Sep 2018 → Jun 2024	plasma cell myeloma	Swedish Medical Center	Unknown	No outcome recorded
Phase 2	NCT03353298 Comparator	Jan 2018 → Sep 2020	—	Oslo University Hospital	Completed	No outcome recorded
Phase 2	NCT02661035 Background	Mar 2017 → Apr 2023	Burkitt lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +8	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT02991898 Background	Feb 2017 → Jun 2019	Burkitt lymphoma, Hodgkins lymphoma, T-cell and NK-cell neoplasm, acute biphenotypic leukemia +10	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT02063997 Comparator	Mar 2014 → Jan 2015	gout	Gilead Sciences	Completed	Met primary
Phase 2	NCT04983160 Comparator	Feb 2014 → Apr 2016	chronic kidney disease	Maimónides Biomedical Research Institute of Córdoba	Completed	No outcome recorded
Phase 2	NCT01637623 Comparator	Jun 2012 → Jun 2015	hypertensive disorder, obstructive sleep apnea syndrome	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 2	NCT01464359 Background	Oct 2011 → Oct 2013	acute myeloid leukemia	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01564277 Background	Sep 2011 → May 2015	Burkitt lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) +3	Roswell Park Cancer Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01399008 Background	Jun 2011 → Feb 2012	gout	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT01157936 Comparator	Jul 2010 → Feb 2011	metabolic syndrome X	Instituto Nacional de Cardiologia Ignacio Chavez	Completed	No outcome recorded
Phase 2	NCT01109121 Comparator	Jun → Dec 2010	gout	Nuon Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT00987415 Comparator	May 2010 → Dec 2013	symptomatic heart failure	Duke University	Completed	No outcome recorded
Phase 2	NCT01077284 Comparator	Feb 2010 → Nov 2011	nephrolithiasis, calcium oxalate	Takeda	Completed	Met primary
Phase 2	NCT01052987 Comparator	Jan → Jun 2010	gout	Nuon Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01001338 Background	Oct 2009 → Jan 2011	gout	Ardea Biosciences, Inc.	Completed	Met primary
Phase 2	NCT00899431 Comparator	May 2009 → Oct 2018	B-cell chronic lymphocytic leukemia	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00819585 Background	Dec 2008 → Aug 2010	gout	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00639756 Comparator	Jun → Aug 2008	metabolic syndrome X	Hospital Mateo Orfila	Completed	No outcome recorded
Phase 2	NCT00652899 Background	Mar 2008 → Aug 2009	fallopian tube cancer, ovarian cancer, peritoneum cancer	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00109837 Background	Apr 2005 → Nov 2010	leukemia	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 2	NCT00053196 Background	Dec 2002 → Nov 2006	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell myeloma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00276003 Background	Aug 2002 → Jun 2005	cancer, non-Hodgkin lymphoma	University of New Mexico	Completed	No outcome recorded
Phase 2	NCT00039130 Background	May 2002 → Sep 2010	leukemia, lymphoma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00003700 Background	Jan 1999 → Feb 2004	lymphoid leukemia	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2/3	NCT07574060 Comparator	May 2026 → May 2027 expected	major depressive disorder	Tanta University	Not yet recruiting	No outcome recorded
Phase 2/3	NCT06276556 Comparator	Apr → Sep 2024	gout	Atom Therapeutics Co., Ltd	Terminated	No outcome recorded Stop: Business
Phase 2/3	NCT05818085 Comparator	Aug 2023 → Jan 2025	gout	Atom Therapeutics Co., Ltd	Completed	No outcome recorded
Phase 2/3	NCT05511766 Comparator	Nov 2022 → Apr 2024	cirrhosis of liver, hepatic encephalopathy, infectious peritonitis, varicose disease	Tanta University	Unknown	No outcome recorded
Phase 2/3	NCT05545670 Comparator	Jun 2022 → Feb 2023	cirrhosis of liver	Tanta University	Completed	No outcome recorded
Phase 2/3	NCT05828836 Comparator	Jun 2022 → Jan 2023	cirrhosis of liver	Tanta University	Completed	No outcome recorded
Phase 2/3	NCT04368819 Comparator	Mar → Sep 2021	—	Ministry of Health, Brazil	Unknown	No outcome recorded
Phase 2/3	NCT02129764 Comparator	Dec 2013 → Feb 2018	symptomatic heart failure	Hebei Medical University	Completed	No outcome recorded
Phase 2/3	NCT01052272 Comparator	Jul 2005 → Nov 2010	diabetes mellitus	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 3	NCT07089888 Comparator	Aug 2025 → Dec 2027 expected	gout	Crystalys Therapeutics	Recruiting	No outcome recorded
Phase 3	NCT07089875 Comparator	Aug 2025 → Nov 2027 expected	gout	Crystalys Therapeutics	Recruiting	No outcome recorded
Phase 3	NCT05943821 Comparator	Sep 2023 → Jul 2028 expected	cardiovascular disorder	Poznan University of Medical Sciences	Recruiting	No outcome recorded
Phase 3	NCT05586971 Comparator	Mar 2023 → May 2025	gout	LG Chem	Completed	No outcome recorded
Phase 3	NCT04956432 Comparator	Jun 2021 → Dec 2023	gout	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT04217421 Comparator	Feb 2020 → Oct 2026 expected	congenital heart disease	dr. M.J.N.L. Benders	Recruiting	No outcome recorded
Phase 3	NCT04052932 Comparator	Jul 2019 → Jul 2021	gout	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03162653 Comparator	Mar 2018 → Jan 2026	brain hypoxia - ischemia, perinatal disease	University Hospital Tuebingen	Unknown	No outcome recorded
Phase 3	NCT03150693 Background	Sep 2017 → Mar 2027 expected	B-cell acute lymphoblastic leukemia	Alliance for Clinical Trials in Oncology	Recruiting	No outcome recorded
Phase 3	NCT01724528 Comparator	Oct 2012 → Oct 2013	tumor lysis syndrome	Menarini Group	Completed	Mixed
Phase 3	NCT01510158 Comparator	Jan 2012 → Jul 2014	gout	Ardea Biosciences, Inc.	Completed	Met primary
Phase 3	NCT01493531 Background	Dec 2011 → May 2014	gout	Ardea Biosciences, Inc.	Completed	Met primary
Phase 3	NCT01459796 Background	Nov 2011 → Jun 2013	gout	Regeneron Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT02082769 Comparator	Jul 2011 → Oct 2013	gout	Xijing Hospital	Completed	Met primary
Phase 3	NCT01736514 Comparator	Mar 2011 → Feb 2012	gout	Astellas Pharma Taiwan, Inc.	Completed	No outcome recorded
Phase 3	NCT01101035 Comparator	Apr 2010 → May 2017	cardiovascular disorder	Takeda	Completed	Met primary
Phase 3	NCT00607152 Comparator	Oct 2007 → Jan 2009	—	Sanofi	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00430248 Comparator	Feb 2007 → Mar 2008	gout	Takeda	Completed	Met primary
Phase 3	NCT00241839 Comparator	Aug 2005 → May 2011	heart disorder, hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 3	NCT00175019 Comparator	Jul 2003 → Feb 2007	gout	Takeda	Completed	No outcome recorded
Phase 3	NCT00174915 Comparator	Feb 2003 → Apr 2004	gout	Takeda	Completed	Met primary
Phase 3	NCT00102440 Comparator	Jul 2002 → Feb 2004	gout	Takeda	Completed	Met primary
Phase 3	NCT00000658 Background	? → Feb 1996	HIV infectious disease, non-Hodgkin lymphoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 4	NCT07369622 Comparator	Jan 2026 → Jun 2027 expected	gout	Haiphong University of Medicine and Pharmacy	Not yet recruiting	No outcome recorded
Phase 4	NCT07800598 Comparator	Sep 2025 → Dec 2026 expected	cirrhosis of liver	Bangladesh Medical University	Recruiting	No outcome recorded
Phase 4	NCT06966635 Background	Apr 2024 → Dec 2025 overdue	gout, nephrolithiasis	Huashan Hospital	Recruiting	No outcome recorded
Phase 4	NCT04875702 Comparator	Feb 2024 → Sep 2028 expected	gout	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 4	NCT03700645 Comparator	Dec 2018 → Dec 2019	coronary artery disorder, diabetes mellitus, ischemic disease	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 4	NCT03336203 Comparator	Oct 2017 → Dec 2022	chronic kidney disease, gout	Medical Practice Prof D. Ivanov	Unknown	No outcome recorded
Phase 4	NCT03226899 Comparator	Jul 2017 → Feb 2019	chronic kidney disease, gout	Ironwood Pharmaceuticals, Inc.	Terminated	No outcome recorded Stop: Business
Phase 4	NCT02579096 Comparator	Mar 2017 → Feb 2021	chronic kidney disease, gout	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT02500641 Comparator	Aug 2015 → May 2017	gout	Menarini International Operations Luxembourg SA	Completed	Missed primary
Phase 4	NCT01550107 Comparator	Feb 2015 → Aug 2017	muscular atrophy	University of Dundee	Completed	No outcome recorded
Phase 4	NCT02237339 Comparator	Sep 2014 → Jun 2017	essential hypertension	University of Dundee	Completed	No outcome recorded
Phase 4	NCT02829177 Comparator	Sep 2014 → Aug 2016	diabetic kidney disease, type 1 diabetes mellitus	Peter Rossing	Completed	No outcome recorded
Phase 4	NCT02600780 Comparator	Nov 2013 → Dec 2014	—	Getz Pharma	Completed	No outcome recorded
Phase 4	NCT01951404 Comparator	Sep 2013 → Aug 2016	end stage renal failure	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01451645 Background	Oct 2011 → Aug 2012	gout	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01147705 Comparator	Feb 2011 → Jul 2012	peripheral arterial disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01332799 Comparator	Feb 2011 → Aug 2018	disease related to solid organ transplantation	University of Iowa	Terminated	No outcome recorded Stop: Business
Phase 4	NCT00919243 Comparator	Feb 2009 → Jul 2010	heart failure	Hebei Medical University	Completed	Missed primary
Phase 4	NCT00688480 Comparator	Jan 2008 → Aug 2009	kidney disorder	A. D. Struthers	Completed	No outcome recorded
Phase 4	NCT01988402 Comparator	Dec 2007 → Jun 2013	gout	59th Medical Wing	Completed	No outcome recorded
Phase 4	NCT01310673 Comparator	Jan 1998 → Jul 2009	gout	White River Junction Veterans Affairs Medical Center	Completed	No outcome recorded
Phase 4	NCT00997542 Comparator	—	heart failure	National Heart and Lung Institute	Completed	No outcome recorded
—	NCT07850713 Comparator	May → Nov 2026 expected	chronic kidney disease	Nishtar Medical University	Active not recruiting	No outcome recorded
—	NCT07326839 Background	Dec 2025 → Nov 2027 expected	gout, obesity disorder	XueMei Guo	Not yet recruiting	No outcome recorded
—	NCT07177898 Comparator	May 2023 → Sep 2024	diabetic kidney disease	Narowal Medical College	Completed	No outcome recorded
—	NCT05601271 Comparator	Mar 2021 → Mar 2025	chronic kidney disease, renal osteodystrophy	University of Sao Paulo General Hospital	Completed	No outcome recorded
—	NCT03385135 Comparator	Dec 2017 → Mar 2018	coronary artery disorder, diabetes mellitus	University Tunis El Manar	Unknown	No outcome recorded
—	NCT02008968 Comparator	Dec 2013 → Jul 2014	prediabetes syndrome	Istanbul Medeniyet University	Unknown	No outcome recorded
—	NCT01685411 Background	Jan 2013 → Feb 2020	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT02992652 Comparator	Jan 2011 → Dec 2014	—	Ain Shams University	Completed	No outcome recorded
—	NCT01228903 Comparator	Oct 2010 → Sep 2016	kidney disorder	University of Colorado, Denver	Completed	No outcome recorded
—	NCT00000703 Background	? → Mar 1990	HIV infectious disease, non-Hodgkin lymphoma	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 6

Date	Issuer	Release
2023-11-07	Arthrosi Therapeutics	Results Arthrosi to Present Positive Phase 2 Data for its Novel Selective URAT1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023 arthrosi.com ↗ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for gout that dissolve uric acid crystals and prevent joint damage, today announced new clinical data from its phase 2 AR882-203 study in patients with tophaceous gout.
2017-10-09	BioCryst Pharmaceuticals	Results BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined with Allopurinol in Patients with Gout biocryst.com ↗ A dose-response was demonstrated for both BCX4208 and allopurinol, and the combination of BCX4208 and allopurinol was shown to be superior to either drug alone in sUA reduction.
2017-10-09	BioCryst Pharmaceuticals	Results BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology biocryst.com ↗ Poster THU0011 titled "BCX4208 Shows Synergistic Reductions in Serum Uric Acid in Gout Patients When Combined with Allopurinol" by A. Hollister et al. additionally concludes that the combination of BCX4208 and allopurinol brought a larger proportion of gout patients to serum uric acid level below 6 mg/dL than allopurinol alone.
2017-10-09	BioCryst Pharmaceuticals	Results BioCryst to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology biocryst.com ↗ BCX4208 Shows Synergistic Reductions in Serum Uric Acid (sUA) in Gout Patients when Combined with Allopurinol
2017-10-09	BioCryst Pharmaceuticals	Results BioCryst Pharmaceuticals Presents New BCX4208 Gout Data at the 2011 ACR/ARHP Annual Scientific Meeting biocryst.com ↗ When added to allopurinol 300 mg, BCX4208 was superior to allopurinol plus placebo (p=0.009 overall).
2014-08-13	AstraZeneca	Results AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients astrazeneca.com ↗ In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met the primary endpoint

All press releases naming this drug 10 releases

Date	Issuer	Release
2023-12-15	Lupin Limited	Lupin Receives Approval from U.S. FDA for Allopurinol Tablets lupin.com ↗
2023-11-07	Arthrosi Therapeutics	Arthrosi to Present Positive Phase 2 Data for its Novel Selective URAT1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023 arthrosi.com ↗
2017-10-09	BioCryst Pharmaceuticals	BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined with Allopurinol in Patients with Gout biocryst.com ↗
2017-10-09	BioCryst Pharmaceuticals	BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology biocryst.com ↗
2017-10-09	BioCryst Pharmaceuticals	BioCryst to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology biocryst.com ↗
2017-10-09	BioCryst Pharmaceuticals	BioCryst Pharmaceuticals Presents New BCX4208 Gout Data at the 2011 ACR/ARHP Annual Scientific Meeting biocryst.com ↗
2017-10-09	BioCryst Pharmaceuticals	BioCryst Initiates a Phase 2b Study of BCX4208 as Add-on Therapy in Gout Patients Not Responding to Allopurinol Alone biocryst.com ↗
2017-10-09	BioCryst Pharmaceuticals	BioCryst Initiates a Phase 2 Study of BCX4208 Alone and in Combination with Allopurinol in Patients with Gout biocryst.com ↗
2017-10-09	BioCryst Pharmaceuticals	BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to Allopurinol Alone biocryst.com ↗
2014-08-13	AstraZeneca	AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients astrazeneca.com ↗

Evidence & citations 38 cited values

Every value below carries the sentence it was read from. 184 sources stand behind the page.

Field	Value	Cited text
Known as	Allopurinol	“Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion...” NCT06966635 ↗ 179 “This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects.” NCT00823199 ↗ “antioxidant treatment with allopurinol, α-lipoic acid and nicotinamide, or placebo.” PMID 23740194 ↗ Jun 2013 “For uric acid \>800mg male, \>750mg female: allopurinol 300mg.” NCT05365477 ↗ “Allopurinol on day -7 to day 0” NCT02991898 ↗ “allopurinol” NCT03226899 ↗ NCT03385135 ↗ NCT00899431 ↗ NCT01391325 ↗ NCT06276556 ↗ NCT03745729 ↗ Show 169 more sources
Known as	1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one	“This site will receive 10 µM allopurinol (1H-pyrazolo\[3,4-d\]pyrimidin-4(2H)-one)at an infusion rate of 2 µl/min.” NCT03680573 ↗
Known as	Acepurin	“the company that holds the Dutch marketing authorization registration for Acepurin® (allopurinol 1 g/100 ml) for intravenous application for the treatment of gout.” PMID 38267942 ↗ Jan 2024
Known as	ALLO	“BACKGROUND: Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result...” PMID 35274092 ↗ Mar 2022 1 “Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)” NCT04155918 ↗
Known as	Allopurinol (Allosig, Progout, Zyloprim)	“Allopurinol (Allosig®, Progout®, Zyloprim®)” NCT04155918 ↗
Known as	Allopurinol component of duzallo	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	ALLOPURINOL SODIUM	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Allopurinol sodium salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Allopurinol Tablet	“Drug: Allopurinol Tablet” NCT07033533 ↗
Known as	Allopurinol: Mephanol (R) 100 mg tablets	“Allopurinol: Mephanol (R) 100 mg tablets” NCT00849368 ↗
Known as	Allopurinolum	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Aloprim	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Alopurinol	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Aloral	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Aluline 100	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Aluline 300	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	BW 56-158	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Caplenal	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Cosuric	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Hamarin 100	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Hamarin 300	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Ledopur	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Lopurin	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	NSC-101655	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	NSC-108836	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	NSC-1390	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Suspendol	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Takanarumin	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Uricto	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Xanthomax-100	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Xanthomax-300	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Zyloprim	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Zyloric	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Known as	Zyloric-300	ChEMBL registry synonym — accepted as the source's own label CHEMBL1467 ↗
Action	Inhibit	“This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.” NCT00181155 ↗ 1 “Xanthine dehydrogenase inhibitor” CHEMBL1467 ↗
Modality	Small molecule	“The purine analogue, allopurinol, has been in clinical use for more than 30 years as an inhibitor of xanthine oxidase (XO) in the treatment of hyperuricemia and gout.” PMID 15698861 ↗ Jan 2005
Route	Oral	“PO q day” NCT00003700 ↗
Target	XDH	“Xanthine dehydrogenase inhibitor” CHEMBL1467 ↗